DHL Supply Chain has launched a new EUR 10 million (USD 11.2 million) Pharma Hub in Singapore, marking a significant expansion of its life sciences and healthcare (LSHC) logistics infrastructure in the Asia Pacific region. This dedicated 8,200-square-meter facility, located at 8 Jurong Pier near Tuas Bio-Medical Park, is part of DHL Group’s broader EUR 500 million (USD 560 million) investment in the region aimed at supporting the rapidly growing demand for transformative healthcare solutions. The hub features specialized temperature-controlled zones, including ambient and cold rooms, ensuring precise storage and handling of sensitive pharmaceutical products in compliance with Good Manufacturing Practice (GMP) standards. Advanced cold chain infrastructure, such as airtight loading docks and dedicated anterooms, guarantees uninterrupted temperature stability throughout the logistics process.
Strategically positioned to offer seamless connectivity to both Changi Airport and Tuas Mega Port, the Pharma Hub is designed to facilitate efficient regional and global distribution for pharmaceutical partners. The facility will also enable value-added services such as redressing activities in the future, further strengthening Singapore’s role as a regional logistics and innovation hub for the life sciences sector. DHL’s investment reflects its commitment to supporting Asia Pacific’s healthcare market, which is projected to reach USD 138 billion by 2030, driven by longer lifespans, personalized treatments, and rising consumer expectations.
The new hub is a cornerstone of DHL’s Strategy 2030 and the introduction of its DHL Health Logistics sector brand, which aims to drive cross-divisional growth and enhance the company’s ability to deliver life-saving medicines and healthcare products quickly and reliably. With over 36,000 square meters of warehouse space in Singapore now dedicated to LSHC operations, DHL Supply Chain supports regional distribution centers for multinational medical device companies, clinical trial logistics, and other value-added services. This infrastructure investment is complemented by similar projects across Asia Pacific, including new sites in Australia, New Zealand, South Korea, and India.
DHL’s expansion in Singapore reinstates the country’s ambitions to be a global leader in life sciences and medtech innovation. By building strong infrastructure, employing skilled personnel, and implementing innovative logistics solutions, DHL is enabling its customers to focus on patient care and innovation while managing the complexities of supply chain management across all logistics touchpoints.
(Source: Manufacturing Today)
